Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2023-11-15 Interim / Quarterly Rep…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Skrócone sprawozdanie finansowe Pure Biologics S.A. za okres 01.07-30.09.2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Śródroczne skrócone sprawozdanie finansowe' (Interim Condensed Financial Statement) for the period 01.07.2023 - 30.09.2023. It contains detailed financial statements including the Statement of Profit or Loss, Statement of Financial Position, and explanatory notes. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2023
2023-11-15 Polish
Jednostkowy raport kwartalny Pure Biologics S.A. - 3Q 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Jednostkowy raport kwartalny' (Individual Quarterly Report) for the period 01.07.2023 - 30.09.2023. It contains detailed sections on company management, business operations, R&D projects, and financial commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2023
2023-11-15 Polish
Powiadomienie 19 MAR - Romuald Harwas
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). Article 19 of the Market Abuse Regulation (MAR) mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs). The content details a transaction (Subscription of warrants) by a member of the management board ('wiceprezes zarządu'), Romuald Harwas, involving shares/securities of PURE BIOLOGICS SPÓŁKA AKCYJNA. This specific type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS).
2023-10-06 Polish
Powiadomienie 19 MAR - Petrus Spee
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). This regulation (Market Abuse Regulation) mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs). The content details a transaction (Subscription of 16,000 units) by a member of the management board ('Wiceprezes Zarządu') of PURE BIOLOGICS SPÓŁKA AKCYJNA. This specific type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS).
2023-10-06 Polish
Powiadomienie o transakcjach wykonywanych przez osoby pełniące obowiązki zarządcze w Spółce - Content (PL)
Director's Dealing Classification · 95% confidence The document text is very short (578 characters) and explicitly states that the Management Board received notifications regarding the subscription warrants being taken up by management personnel (Vice Presidents) under a motivational program, referencing Article 19(3) of the MAR Regulation. Crucially, it states: "Treść otrzymanych powiadomień Spółka przekazuje w załączeniu do niniejszego raportu bieżącego" (The Company transmits the content of the received notifications attached to this current report). This structure—a brief announcement referencing attached insider transaction details—strongly suggests it is not the detailed transaction report itself, but rather an announcement about the filing of such information. Insider transaction reports (Director's Dealing) are typically classified as DIRS. However, since this document is merely announcing the attachment of the actual notifications (similar to the 'Menu vs Meal' rule), and it is a 'raport bieżący' (current report) concerning insider dealings, it fits best under the general regulatory announcement category, RNS, or potentially DIRS if the attached content is the primary focus. Given the context of MAR notifications regarding management transactions, DIRS is the most specific category for the *subject matter* (Director's Dealing). However, the text itself is an announcement of the filing, which often defaults to RNS if DIRS is reserved for the actual form (like Form 4 in the US). Since DIRS covers 'Report of personal share transactions by company directors and executives (insider trades)', and this is the announcement of such a report, DIRS is the most appropriate specific classification for the *content* being reported, even if the wrapper is an announcement. I will classify it as DIRS based on the subject matter (insider dealing notification under MAR).
2023-10-06 Polish
Uchwała Emisyjna Pure Biologics S.A. z dnia 13.09.2023
Capital/Financing Update Classification · 99% confidence The document is a formal resolution ("Uchwała") from the Management Board of Pure Biologics S.A. dated September 13, 2023. The core subject is the 'increase of the share capital' ('podwyższenia kapitału zakładowego') through the issuance of new shares ('emisji nowych akcji') via a public offering ('oferty publicznej'), including the exclusion of pre-emptive rights ('wyłączeniem prawa poboru'). This directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), as it details a specific corporate action regarding capital.
2023-09-13 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.